3-benzoyl-10-bromo-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - Pyrroloazepines
• 英文名称: 3-benzoyl-10-bromo-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole
• 英文别名: (10-bromo-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indol-3-yl)-phenylmethanone
• 化学式: C₁₉H₁₇BrN₂O
• 分子量: 369.261
• InChiKey: PPBUTQXRZJZDNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  36.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-benzoyl-10-bromo-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 在 三氯化铝 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以13.6 g (94%)的产率得到3-benzyl-10-bromo-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole
  参考文献：
  名称：

  Substituted azepino[4,5b] indoline derivatives

  摘要：

  该发明提供了Formula (I)的化合物： 其中R1-R4，p和q的取值如规范中描述的任何值，以及其药用盐，以及含有这种化合物或盐的药用组合物。这些化合物和盐是5-HT配体，对于治疗哺乳动物中涉及5-HT受体活性的疾病、紊乱和/或症状是有用的。这些化合物和盐特别适用于治疗中枢神经系统疾病。

  公开号：

  US20020077318A1

文献信息

• Substituted azepino[4,5b]indole derivatives
  申请人：Pharmacia & UpJohn Company

  公开号：US20030220321A1

  公开（公告）日：2003-11-27

  Disclosed are compounds of Formula (I): 1 wherein R 1 -R 4 , p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.

  本发明涉及公式（I）的化合物：其中R1-R4，p和q的任何值均如说明书所述，以及其制备的药物盐和包含这些化合物或盐的药物组合物。这些化合物和盐是5-HT配体，并且对于治疗哺乳动物中涉及5-HT受体活性的疾病，障碍和/或状况非常有用。这些化合物和盐特别适用于治疗中枢神经系统疾病。
• Substituted azepino[4,5b]indoline derivatives
  申请人：Pharmacia & UpJohn Company

  公开号：US20030225058A1

  公开（公告）日：2003-12-04

  The invention provides compounds of Formula (I): 1 wherein R 1 -R 4 , p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.

  本发明提供了公式(I)的化合物：1其中R1-R4，p和q具有规范中描述的任何值，以及其药物盐，以及包含该类化合物或盐的药物组合物。这些化合物和盐是5-HT配体，可用于治疗哺乳动物中涉及5-HT受体活性的疾病，紊乱和/或病况。这些化合物和盐特别适用于治疗中枢神经系统疾病。
• Substituted azepino[4,5b]indole derivatives
  申请人：Pharmacia & Upjohn Company

  公开号：US06583135B2

  公开（公告）日：2003-06-24

  Disclosed are compounds of Formula (I): wherein R1-R4, p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.

  本发明公开了式(I)的化合物：其中R1-R4，p和q具有规范中描述的任何值，以及其药物盐，以及包含这样的化合物或盐的药物组合物。这些化合物和盐是5-HT配体，可用于治疗哺乳动物中涉及5-HT受体活性的疾病，障碍和/或状况。这些化合物和盐特别适用于治疗中枢神经系统疾病。
• Substituted azepino[4,5b]indoline derivatives
  申请人：Pharmacia & Upjohn Company

  公开号：US06586421B2

  公开（公告）日：2003-07-01

  The invention provides compounds of Formula (I): wherein R1-R4, p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.

  本发明提供了式(I)的化合物：其中R1-R4，p和q具有规范中描述的任何值，以及其药物盐和含有这种化合物或盐的药物组合物。这些化合物和盐是5-HT配体，可用于治疗哺乳动物中涉及5-HT受体活性的疾病，疾患和/或情况。这些化合物和盐特别适用于治疗中枢神经系统疾病。
• SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1319005A2

  公开（公告）日：2003-06-18